RT Journal Article SR Electronic T1 A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.02.05.21251182 DO 10.1101/2021.02.05.21251182 A1 Leonidas Stamatatos A1 Julie Czartoski A1 Yu-Hsin Wan A1 Leah J. Homad A1 Vanessa Rubin A1 Hayley Glantz A1 Moni Neradilek A1 Emilie Seydoux A1 Madeleine F. Jennewein A1 Anna J. MacCamy A1 Junli Feng A1 Gregory Mize A1 Stephen C. De Rosa A1 Andrés Finzi A1 Maria P. Lemos A1 Kristen W. Cohen A1 Zoe Moodie A1 M. Juliana McElrath A1 Andrew T. McGuire YR 2021 UL http://medrxiv.org/content/early/2021/03/10/2021.02.05.21251182.abstract AB Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naïve donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Pre-vaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was due to antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses, but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by generous donations to Fred Hutch COVID-19 Research Fund, and to MJM from the Paul G. Allen Family Foundation, the Joel D. Meyers Endowed Chair, and NIAID UM1 AI068618-14S1, 2UM1 AI069481-15, and UM1A057266-S1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Peripheral blood mononuclear cells (PBMCs) and serum were collected from donors who recovered from SARS-CoV-2 infection and were the first 10 who then subsequently received a SARS-CoV-2 vaccine as part of the study: Seattle COVID-19 Cohort Study to Evaluate Immune Responses in Persons at Risk and Peripheral blood mononuclear cells (PBMCs) and serum were collected from participants enrolled in the longitudinal study: Seattle COVID-19 Cohort Study to Evaluate Immune Responses in Persons at Risk and with SARS-CoV-2 Infection. Eligibility criteria included adults in the greater Seattle area at risk for SARS-CoV2 infection or those diagnosed with COVID-19 by a SARS CoV-2 PCR assay University of Washington multiplex PCR reaction using CDC approved primers/probes for the virus nucleocapsid (N) gene, N1 and N2) or blood antibody test (SARS CoV-2 IgG Architect, Abbot). Fifteen participants who recovered from SARS-CoV-2 and 13 that were SARS-CoV2 negative were selected from among those that were the first to receive two doses of an Emergency Use Authorization COVID-19 vaccine. Samples were selected based on availability. Sample sizes, randomization, or blinding were not pre-determined, nor were there specific inclusion/exclusion criteria. Serum or plasma from pre-pandemic controls were blindly selected at random from the study: Establishing Immunologic Assays for Determining HIV-1 Prevention and Control, with no considerations made for age, or sex. Both studies were recruited at the Seattle Vaccine Trials Unit (Seattle, Washington, USA). Informed consent was obtained from all participants and the Fred Hutchinson Cancer Research Center Institutional Review Board approved the studies and procedures (IR10440 and IR5567). Study data were collected and managed using REDCap electronic data capture tools hosted at Fred Hutchinson Cancer Research Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is provided in the manuscript.